SkinBioTherapeutics (LSE: SBTX) is growing again, but will cash last long enough?

SkinBioTherapeutics plc (LSE: SBTX) has emerged from an investigation, a trading suspension and a major restatement with its operating businesses intact, but the investment case now depends on whether new management can restore financial credibility before cash becomes a more urgent constraint. The AIM-listed skin health group owns consumer products, specialist skincare operations, manufacturing capabilities and microbiome intellectual property, including the technology behind Croda International plc’s Zenakine ingredient. Its next major catalyst is the promised reset of market guidance later in 2026, which should reveal whether underlying revenue growth can produce a credible route toward profitability and adequate funding.

SkinBioTherapeutics shares closed at 10.50 pence on July 9, valuing the company at approximately £27.21 million. SBTX stock was unchanged across the five completed trading sessions from July 2, but it remained around 50% above its June 10 closing price of 7 pence following the resumption of trading.

That recovery requires context. The shares remain below the 52-week high of 23 pence and significantly below the levels reached before February’s disclosure concerning incorrectly recognised royalty income and the conduct of former chief executive Stuart Ashman. The market is therefore pricing some probability of operational recovery, but it is still applying a substantial credibility and funding discount.

What does SkinBioTherapeutics actually sell and how is its business model differentiated?

SkinBioTherapeutics began as an intellectual property-led life science company built around research into the human microbiome. Its SkinBiotix platform originated from work at the University of Manchester and uses bacterial lysates, which are preparations derived from probiotic bacteria, to support skin barrier function and influence biological pathways connected with inflammation and skin health.

The group now operates through a wider commercial structure rather than relying entirely on a single future licensing breakthrough. It sells oral supplements through AxisBiotix, specialist topical products through Dermatonics and contract manufacturing services through Bio-Tech Solutions. It also retains the potential to earn licensing and royalty income from intellectual property commercialised by partners.

This combination differentiates SkinBioTherapeutics from a conventional pre-revenue biotechnology company. Dermatonics and Bio-Tech Solutions already generate product and service revenue, while AxisBiotix has direct-to-consumer and retail distribution. SkinBiotix offers a potentially higher-margin licensing route if ingredients based on the technology gain meaningful commercial adoption.

The difficulty is that these businesses have different economics. Contract manufacturing can produce recurring revenue but may require inventory, labour and operational investment. Consumer products require advertising, packaging, retailer support and customer-acquisition spending. Licensing can offer attractive margins, but revenue depends on the sales performance and reporting cycles of external partners.

The group must therefore prove that its collection of assets forms a coherent skin health platform rather than a portfolio of small businesses consuming central costs. The strategic value will come from using Bio-Tech Solutions’ manufacturing capacity, Dermatonics’ distribution relationships and SkinBioTherapeutics’ intellectual property to create commercial overlap. Without that integration, the acquisitions could add revenue without solving the group’s profitability challenge.

Why is the promised FY2026 guidance reset the next major catalyst for SBTX investors?

SkinBioTherapeutics previously expected FY2026 revenue of £6.2 million and adjusted earnings before interest, tax, depreciation and amortisation of £700,000. Those expectations were withdrawn after the investigation found that £770,000 of accrued royalty income had been incorrectly included in the FY2025 accounts.

The board subsequently indicated that FY2026 performance would be significantly below the earlier market expectations. It has committed to issuing new guidance later in 2026, making that update the clearest forthcoming valuation event for the shares.

Investors need more than a replacement revenue number. The new guidance must explain the contribution expected from Dermatonics, Bio-Tech Solutions, AxisBiotix and confirmed licensing income. It should also distinguish ordinary operating expenditure from exceptional investigation, legal and governance costs.

The milestone sequence begins with permanent leadership appointments and the completion of strengthened financial controls. The company then needs to provide its FY2026 trading position, updated cash information and revised expectations. Audited FY2026 results and restated FY2025 accounts should subsequently show whether the remediation work has produced reliable reporting.

The market will also look for evidence concerning the FY2027 funding position. Even a respectable revenue figure may not produce a rerating if investors conclude that another equity raise is likely before the group becomes cash-generative. Conversely, conservative guidance supported by visible revenue and disciplined costs could be more valuable than an ambitious forecast carrying another credibility risk.

The most important change is cultural as much as financial. SkinBioTherapeutics is no longer being rewarded for distant commercial possibilities alone. The next management team will need to establish measurable targets, report progress consistently and avoid relying on revenue that has not been confirmed.

What does the FY2025 restatement mean for governance credibility and future reporting?

The investigation concluded that £770,000 of accrued royalty revenue had been inappropriately recognised in the FY2025 financial statements. Documentation supporting that revenue was identified as having been fabricated by the former chief executive, with no evidence disclosed that other individuals were involved in or aware of the fabrication.

The adjustment reduced FY2025 revenue from £4.64 million to £3.87 million. The restated adjusted EBITDA loss increased to £1.40 million from the previously reported £410,000 loss, reflecting the royalty reversal and adjustments connected with director bonuses.

The investigation did not identify problems with the group’s reported cash balances. That distinction matters because it suggests the issue concerned revenue recognition and governance rather than missing cash. Nevertheless, weak controls allowed unsupported income to pass through the reporting process, which damaged confidence in forecasts and management oversight.

Governance reform is now central to the equity thesis. Saffery LLP was appointed to audit the restated FY2025 statements alongside the FY2026 accounts, while the board began implementing recommendations covering financial reporting, processes and oversight.

Leadership has also changed rapidly. Rachel Parsonage became interim chief executive, Alyson Levett assumed the acting chair role and former chief financial officer Emily Bertram left at the end of June after helping identify and escalate the original concerns. An experienced interim finance executive has been engaged while a permanent chief financial officer is recruited.

These changes reduce the risk of preserving an ineffective structure, but they also create continuity risk. SkinBioTherapeutics entered July with an interim chair, interim chief executive and interim chief financial officer. The business must manage operations, partnerships, audit work and strategic planning while recruiting a permanent leadership team.

For retail investors, the correct response is neither to assume that every historic figure is unreliable nor to declare the problem fully resolved because the investigation ended. Confidence should rebuild gradually through audited accounts, conservative guidance, better disclosure and repeated delivery.

Can Zenakine royalties from Croda become the commercial engine investors originally expected?

Zenakine is based on SkinBiotix intellectual property and has been developed by Croda International as a biotechnology-derived ingredient targeting the effects of stress on the skin. It was introduced commercially at the In-Cosmetics Global exhibition in April 2025 and later received recognition at the 2026 Cosmetics and Toiletries Allē Awards.

The Croda relationship is important because a global speciality chemicals company can place an ingredient before a much larger network of beauty and personal-care manufacturers than SkinBioTherapeutics could reach independently. The arrangement also offers a capital-light model in which Croda handles manufacturing and commercialisation while SkinBioTherapeutics receives income linked to confirmed activity.

Royalty income could eventually carry stronger incremental margins than product manufacturing. Once the underlying intellectual property and partner relationship are established, additional ingredient sales may not require a matching increase in SkinBioTherapeutics’ operating costs.

However, the accounting episode makes confirmed royalty reporting especially sensitive. Investors are unlikely to credit estimates, implied customer demand or anticipated orders without clear evidence. Revenue should be recognised only as verified partner sales information becomes available.

The near-term valuation question is not whether Zenakine has scientific or industry interest. It is whether commercial adoption by formulation customers becomes large enough to affect SkinBioTherapeutics’ group financial results. Awards and exhibition launches support awareness, but meaningful shareholder value requires recurring orders, wider use in finished products and transparent royalty conversion.

The company is also reviewing opportunities to commercialise its wider intellectual property more aggressively. Additional licensing agreements could diversify dependence on Croda, although negotiations, product development and regulatory work can take considerable time. Investors should therefore treat new intellectual property partnerships as potential upside rather than assume they will solve the immediate cash-flow challenge.

Zenakine remains the most scalable element of the portfolio, but it is also the element over which SkinBioTherapeutics has the least direct commercial control. Croda’s customer adoption, product-launch schedules and sales reporting will determine the pace at which scientific value turns into revenue.

How could Dermatonics and Bio-Tech Solutions change the route toward group profitability?

Dermatonics supplies specialist topical products used in foot care, dry skin and barrier repair. Its customers include the National Health Service, podiatrists and major retailers such as Boots and Superdrug.

The business generated £980,000 of revenue during the first half of FY2026, broadly unchanged from £1 million in the comparable period. Stable demand provides a useful base, but flat sales also show that Dermatonics needs stronger retail, online and international execution to become a major growth driver.

Management is refreshing the brand and improving customer navigation across its product range. This could support better retail positioning and direct sales, although rebranding also requires expenditure before commercial benefits become visible.

Bio-Tech Solutions produced £1.2 million of first-half revenue, compared with £400,000 in the prior comparable period, partly because FY2026 included a full six months of ownership. The operation gives SkinBioTherapeutics manufacturing capabilities and the ability to produce healthcare and cosmetic products for external customers.

The strategic opportunity is to increase manufacturing efficiency while using the facility for more of the group’s own products. Internal manufacturing could improve control over production, packaging and supply, while external contracts could help absorb fixed costs.

The risk is that contract manufacturing tends to be operationally demanding. Machinery upgrades, quality systems, raw materials, working capital and customer concentration can limit margins. Revenue growth must therefore be accompanied by cash generation, not merely higher production volume.

Dermatonics and Bio-Tech Solutions were previously described as operating around cash breakeven. That gives the group a more tangible commercial foundation than its earlier research-led structure, but central corporate expenditure and losses elsewhere can still outweigh subsidiary-level cash generation.

The investment case would strengthen if SkinBioTherapeutics showed that these units can fund their own growth and contribute toward group overheads. It would weaken if repeated capital injections are required to support inventory, upgrades and product launches without a corresponding improvement in operating cash flow.

Does SkinBioTherapeutics have enough cash to reach its next commercial milestones safely?

Cash and cash equivalents stood at £3.1 million at December 31, 2025, before declining to £1.5 million by May 31, 2026. The reduction occurred during a period affected by working-capital requirements, business disruption and approximately £700,000 of investigation costs.

The company’s first-half operating loss was approximately £1 million, although that figure covered the six months to December and preceded much of the investigation expenditure. The cash balance therefore needs to be assessed alongside the group’s cost reductions, subsidiary cash generation, legal spending and expected receipts.

The board has indicated that the FY2026 accounts will be prepared on a going concern basis. That accounting position is relevant, but it should not be interpreted as a guarantee that additional capital will be unnecessary. A going concern assessment may depend on forecasts, cost controls, revenue assumptions and access to funding.

At a market capitalisation of approximately £27 million, SkinBioTherapeutics could theoretically raise additional equity. The practical concern is dilution. A fundraising conducted before renewed guidance and financial credibility are established may require a discount and could transfer a meaningful portion of future upside to new investors.

The alternative is to preserve cash through lower central costs, reduced direct-to-consumer spending, improved manufacturing efficiency and stronger subsidiary contributions. Recovery of investigation-related losses through legal proceedings could provide additional liquidity, but the timing and amount remain uncertain and should not be treated as available funding.

This makes the next cash disclosure as important as the next revenue disclosure. Investors need to know the June year-end cash position, the normalised monthly cash requirement and whether the company has enough liquidity to complete its audit, leadership recruitment and commercial reset.

Funding risk is not proof that a placing is imminent. It is, however, an unavoidable part of the current thesis. SkinBioTherapeutics must either demonstrate that cash consumption has fallen materially or explain how it intends to finance the period before sustainable profitability.

Is the SBTX share price valuing a genuine recovery or merely a temporary relief rally?

The shares closed at 10.50 pence on July 9, representing a market value of approximately £27.21 million. The price was flat over the latest five completed sessions but approximately 50% above the June 10 close of 7 pence.

Part of that recovery reflects the removal of extreme uncertainty. Trading resumed, the investigation was completed, the restatement was quantified and the operating businesses continued functioning. These developments reduced the probability of a more severe governance or accounting outcome.

The shares nevertheless remain around 54% below the 52-week high of 23 pence. That gap indicates that investors have not restored the valuation applied before the accounting problem and withdrawal of guidance.

One visible analyst forecast carries an outperform recommendation and a 29 pence price target. That target implies substantial upside from the current price, but it represents the opinion of only one analyst and should be treated cautiously while company guidance remains under review.

Valuing SkinBioTherapeutics through a conventional earnings multiple is difficult because the group is loss-making and its future margin mix is uncertain. A manufacturing-led revenue increase deserves a different valuation from high-margin licensing income, while a funding requirement could materially change the per-share outcome.

At the current valuation, the market appears to be recognising the commercial value of Dermatonics, Bio-Tech Solutions, AxisBiotix and the Croda relationship while applying discounts for cash risk, governance repair and limited forecasting visibility.

A sustained rerating would probably require three developments together: verified royalty or licensing growth, a credible route to positive group cash flow and permanent leadership capable of delivering reliable reporting. One strong update may lift the shares, but repeated execution will be needed to rebuild a durable valuation.

Why are retail investors still debating SkinBioTherapeutics after the accounting crisis?

SkinBioTherapeutics retains retail interest because it combines a small market capitalisation with recognised commercial partners, consumer products and potentially scalable intellectual property. A meaningful increase in Zenakine royalties or a successful strategy reset could have a large effect on a company valued at approximately £27 million.

The share-price recovery from 7 pence to 10.50 pence has strengthened the view that February’s sell-off may have overestimated damage to the underlying businesses. Supporters point to the concluded investigation, unaffected reported cash balances, 37.4% first-half revenue growth and continued operation of major commercial relationships.

Sceptical investors focus on the decline in cash, the absence of fresh guidance, leadership turnover and the possibility of a discounted fundraising. They also question how quickly AxisBiotix, Dermatonics and Bio-Tech Solutions can move from modest subsidiary performance to group-level profitability.

Croda-related royalties dominate much of the discussion. Some investors see Zenakine as the asset capable of transforming margins, while others argue that the value cannot be assessed without confirmed sales and royalty numbers.

AxisBiotix creates a similar divide. The product has an online subscriber retention rate of approximately 86% and distribution across about 180 Superdrug stores, but first-half sales remained modest at £172,000. The commercial test is whether retail visibility can produce enough repeat purchasing to cover marketing, manufacturing and distribution costs.

Retail interest is also sustained by the wide valuation range created by uncertainty. A company that restores trust, secures cash flow and grows licensing revenue may look inexpensive at the current market capitalisation. A company that requires repeated funding while commercial progress remains slow may continue to destroy value despite owning promising technology.

The most disciplined approach is to follow measurable indicators rather than sentiment. These include year-end cash, verified licensing income, Bio-Tech Solutions margins, Dermatonics growth, AxisBiotix retail sales, permanent leadership appointments and the timing of any capital requirement.

What are the key takeaways for investors watching SkinBioTherapeutics and SBTX?

• SkinBioTherapeutics has completed its investigation and restored trading, but financial credibility must now be rebuilt through audited accounts and consistent delivery.
• HY2026 revenue increased 37.4% to £2.17 million, supported by a full contribution from Bio-Tech Solutions, while the operating loss remained approximately £1 million.
• Cash declined to £1.5 million by May 31, making liquidity, spending discipline and potential dilution important parts of the SBTX investment case.
• The promised FY2026 guidance reset is the next major valuation catalyst because previous expectations of £6.2 million revenue and £700,000 adjusted EBITDA no longer apply.
• Zenakine offers potentially scalable royalty economics through Croda International, but investors need confirmed commercial revenue rather than product-launch expectations.
• Dermatonics and Bio-Tech Solutions provide established revenue and manufacturing capabilities, although they must contribute more cash toward central group costs.
• The 10.50 pence share price reflects a partial recovery from the investigation-driven sell-off, but the market continues to discount governance, funding and execution risks.